The aim of this protocol is to evaluate the effects of romidepsin plus 3BNC117 or romidepsin
alone on delaying or preventing viral rebound in ART-treated HIV-1-infected individuals
during an analytical interruption of ART.
Phase:
Phase 2
Details
Lead Sponsor:
Rockefeller University
Collaborators:
Aarhus University Hospital University Hospital of Cologne